Search Results - "Karaağaç, M"

Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study by Araz, M., Karaağaç, M., Korkmaz, L., Koral, L., İnci, F., Beypinar, I., Uysal, M., Artac, M.

Get full text

The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey by Kilickap, S., Ölmez, ÖF., Cicin, I., Demirci, U., Alan, O., Cabuk, D., Şakalar, T., Tatlı, A.M., Başol Buğdaycı, F., Eralp, Y., Uysal, M., Demirkazık, A., Bilgin, B., Yıldız, B., Karaağaç, M., Okutur, K., Sakin, A.

Get full text

355P The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer (mCRC) patients: A Turkish oncology group (TOG) study by Demirkiran, A., Kılınç, F., Koçak, M.Z., Korkmaz, M., Demirkıran, D., Karakurt Eryılmaz, M., Araz, M., Karaağaç, M., Artac, M.

Get full text

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes by Esin, Ece, Oksuzoglu, B., Bilici, A., Cicin, I., Kostek, O., Kaplan, M. A., Aksoy, S., Aktas, B. Y., Ozdemir, O., Alacacioglu, A., Cabuk, D., Sumbul, A. T., Sakin, A., Paydas, S., Yetisir, E., Er, O., Korkmaz, T., Yildirim, N., Sakalar, T., Demir, H., Artac, M., Karaagac, M., Harputluoglu, H., Bilen, E., Erdur, E., Degirmencioglu, S., Aliyev, A., Cil, T., Olgun, P., Basaran, G., Gumusay, O., Demir, A., Tanrikulu, E., Yumuk, P. F., Imamoglu, Inanc, Oyan, B., Cetin, B., Haksoyler, V., Karadurmus, N., Erturk, I., Evrensel, T., Yilmaz, H., Beypinar, I., Kocer, M., Pilanci, K. N., Seker, M., Urun, Y., Yildirim, N., Eren, T., Demirci, U.

“…Purpose In this study, we aimed to describe the real-life practice outcomes of pertuzumab–trastuzumab–taxane (PTT) combination in visceral organ metastatic,…”
Get full text

1792PComparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study by Araz, M, Karaağaç, M, Korkmaz, L, Koral, L, İnci, F, Beypinar, I, Uysal, M, Artac, M

Get full text

2248 Operated and early stage ampulla vateri tumours: Prognostic assessment by Yildirim, N, Mulazimoglu, E, Yüksel, S, Demirci, N.S, Erdem, G.U, Odabas, H, Ozturk, B, Hacibekiroglu, I, Yazici, O, Karaagac, M, Tanriverdi, O, Ucar, M, Börüban, C, Camci, C, Zengin, N

Get full text

Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology) by Süner, A, Aydın, D, Hacıoğlu, M B, Doğu, G G, İmamoğlu, G I, Menekşe, S, Pilancı, K N, Yazıcı, Ö K, Koca, D, Karaağaç, M, Akyol, M, Akman, T, Ergen, S, Avcı, N, Kaçan, T, Bozkurt, O, Kefeli, U, Urakçı, Z, Araz, M, Arpacı, E, Harputlu, H, Sevinç, A

“…Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes…”
Get more information

Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: a multicenter study of Anatolian Society of Medical Oncology by Seber, S, Turkmen, E, Harputoğlu, H, Yeşil, H, Arpacι, E, Menekşe, S, Pilancι, K, Oruç, Z, Taskoylu, B Y, Gumusay, O, Aksoy, A, Karaagac, M, Ozarslan, E, Yetisyigit, T

“…Central nervous system (CNS) metastasis is a rare event in the course of late stage epithelial ovarian cancer (EOC); however its incidence is increasing in…”
Get more information

1401PThe efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey by Kilickap, S, Ölmez, Ö F, Cicin, I, Demirci, U, Alan, O, Cabuk, D, Şakalar, T, Tatlı, A M, Başol Buğdaycı, F, Eralp, Y, Uysal, M, Demirkazık, A, Bilgin, B, Yıldız, B, Karaağaç, M, Okutur, K, Sakin, A

Get full text

Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study by Artac, M., Korkmaz, L., Coskun, H., Dane, F., Karabulut, B., Karaağaç, M., Çabuk, D., Karabulut, S., Aykan, F., Doruk, H., Avci, N., Turhal, S.

Get full text

1547P - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? by Kilickap, S., Buğdaycı Başal, F., Demirkazik, A., Gursoy, P., Demirci, U., Erman, M., Yumuk, F., Cay Senler, F., Cakar, B., Cicin, I., Ozturk, A., Coskun, H.S., Çubukçu, E., Işıkdoğan, A., Olmez, O.F., Tatlı, A.M., Karaagac, M., Şakalar, T., Eralp, Y., Korkmaz, T.

“…ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we…”
Get full text

1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? by Kilickap, S, Buğdaycı Başal, F, Demirkazik, A, Gursoy, P, Demirci, U, Erman, M, Yumuk, F, Cay Senler, F, Cakar, B, Cicin, I, Ozturk, A, Coskun, H S, Çubukçu, E, Işıkdoğan, A, Olmez, O F, Tatlı, A M, Karaagac, M, Şakalar, T, Eralp, Y, Korkmaz, T

“…Abstract Background ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC…”
Get full text

Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? by Kilickap, S., Buğdaycı Başal, F., Demirkazik, A., Gursoy, P., Demirci, U., Erman, M., Yumuk, F., Cay Senler, F., Cakar, B., Cicin, I., Ozturk, A., Coskun, H.S., Çubukçu, E., Işıkdoğan, A., Olmez, O.F., Tatlı, A.M., Karaagac, M., Şakalar, T., Eralp, Y., Korkmaz, T.

Get full text

Clinical, radiological and laboratory findings in patients with duodenal ulcer, treated with micronized bismuth subnitrate, singly and in combination with antacids by Sezer, R, Ozman, M, Karaagac, M

Get more information

A case of malignant nephrosclerosis without hypertension by KULEY, M, KOCAK, N, KARAAGAC, M

Get more information

Malabsorption syndrome following postoperative gastrocolic fistula. Report of a case by Erol, N, Karaağaç, M, Küley, M, Tuncel, S, Surdum, G

Get more information

A New Endoluminal Resection Technique and Device: Resector Balloon by Karakoca, Yalcin, MD, Karaagac, Guler, MD, Aydemir, Cuneyt, MD, Caner, Cevdet, MD

“…Purpose We have developed a new resection technique and designed a special balloon by which resection of endoluminal airway lesions can be safely and…”
Get full text